October 2022 – Congratulations to Alexis Kiyanda for presenting her BU STaRS research project and winning the Third Place Award at the Region VII Medical Education Conference (RMEC) Research Symposium in CT!
October 2022 – Wonderful time seeing our friends and collaborators at the 2022 NANETS Multidisciplinary NET Medical Symposium in Washington, DC! This year, Dr. Heaphy was part of the NANETS Symposium Planning Committee Leadership and a co-moderator of the “NIH/NCI Research Retreat”.
August 2022 – Congratulations to Alexis Kiyanda for successfully presenting her BU STaRS research project “Differential protein expression of lamin A/C and cytokeratin-19 in Black and White patients with prostate cancer“.
August 2022 – Check out our latest collaborative review articles on PanNET biomarkers: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs) in Human Pathology; Prognostic and predictive biomarkers for pancreatic neuroendocrine tumors in Surgical Pathology Clinics; Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors in Journal of Pathology.
June 2020 – Dr. Heaphy has been appointed as an Assistant Professor in the Department of Pathology & Laboratory Medicine at the Boston University School of Medicine. We look forward to establishing collaborations with our clinical and basic science colleagues in the Department.
June 2020 – We are excited to have two undergraduate students, Elizabeth Nelson and Rachel Choate, virtually join our lab this summer to participate in the Summer Training as Research Scholars Program (STaRS). Welcome Elizabeth and Rachel!
March 2020 – Through collaborative efforts, the Heaphy Lab has contributed to studies in prostate cancer that were published back-to-back this month in Cancer Epidemiology, Biomarkers & Prevention! Check out High extra-tumoral mast cell counts are associated with a higher risk of adverse prostate cancer outcomes and Racial difference in prostate cancer cell telomere lengths in men with higher-grade prostate cancer: a clue to the racial disparity in prostate cancer outcomes.